|Day Low/High||65.48 / 67.79|
|52 Wk Low/High||62.66 / 98.70|
Stocks look past the worst gun shooting in U.S. history on Monday, Oct. 2, to trade at new records.
Stocks begin the new month and quarter with gains on Monday, Oct. 2, as manufacturing conditions hold in expansion territory for another month.
AbbVie (NYSE: ABBV) and Bristol-Myers Squibb Company (NYSE: BMY) today announced a clinical trial collaboration to evaluate the combination of AbbVie's investigational antibody drug conjugate ABBV-399 and...
Jim Cramer is bullish on Arconic, Idexx Laboratories, AbbVie. He's bearish on Fitbit, Qualcomm and Walgreens.
Don't be distracted and start buying high and selling low, says Jim Cramer. A good example? Don't trade Apple, own it.
The most recent short interest data has been released for the 08/15/2017 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Hedge fund managers are out with their top stock picks. So who made the list?
Evercore ISI analyst Josh Schimmer is bullish on biotech.
Jim Cramer is bullish on EPR Properties, Activision Blizzard, AbbVie, and ON Semiconductor.
Cramer says this is not the end of the selloff. That's why you should be mentally and financially ready for panic moves -- and opportunities.
What differentiated traders who were injured yesterday from those able to whether a sudden storm? Diversification.
Stock futures are lower.
U.S. stock futures fall as earnings from Amazon.com disappoint.
Wall Street's first glimpse at the second quarter.
Remarkable data was released from Vertex's triple regiment combination trials.
Tech companies aren't the only ones seeing their shares rise this year.
Investors need to focus on earnings and not be distracted by the circus in Washington, Jim Cramer says.
Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...
The approval of Johnson & Johnson's psoriasis treatment will have an adverse impact on Valeant in the second half of 2017, Wells Fargo argued.
Players include Apple, Google, Microsoft and Samsung.
Samsung's Bioepis unit seeks final approval in Europe of a rheumatoid arthritis drug to compete with Humira.
Jim Cramer doesn't buy the backlash against Amazon. He says Prime is a very powerful tool and an irresistible bargain.
Jim Cramer is bullish on Citigroup, Zoetis, Idexx Labs, AbbVie, Nucor, and Alexion.
The main thrust of the order appears to be easing regulatory hurdles to drug approvals, which could lower the cost of bringing new treatments to market and thus lower prices.
Epizyme sank almost 20% since their last earnings report, but recent developments show positive data from one of its keynote drugs, Tazemetostat
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.